(Part two of a four-part series)

See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes

COMPASS (NASDAQ: CMPS)’ Phase 2 trial published results elicited several comments from experts in the field as well as media coverage -see CNN’s Dr. Sanjay Gupta’s report

Yet, they all agree on one thing: more research is needed to determine psilocybin’s efficacy and safety profile.

Associate professor at UCL Dr. Ravi Das said that the results shown at week 3 were positive yet not ‘spectacular’ for psychiatric treatment and that the study reveals “some evidence for greater incidence of adverse effects” as referred to the three reported cases of suicidal behavior in the highest dose group, and lastly pointed out that there were “significantly fewer severely depressed people in the apparent ‘effective’ (25mg) dose group.” 

The latter critique was somewhat dismissed by Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins, as not significant to the findings.

Dr. Natalie Gukasyan, a psychiatrist and post-doctoral research fellow at that same university, launched a Twitter thread regarding the definition of adverse events in psychedelics and their significance in a relatively small sample of people with TRD.

Yet another thing to consider …

Full story available on Benzinga.com